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Combined resection of primary non-small-cell lung cancer and single brain 
metastasis  reportedly superior to other treatments in prolonging survival 
and disease-free interval. To identify prognostic factors that influenced 
survival we reviewed clinical records and follow-up data of 52 consecutive 
patients with non-small-cell lung cancer and single brain metastasis who 
had been evaluated for combined lung and brain operation: 19 had 
synchronous and 33 metachronous non-small-cell lung cancer and single 
brain metastasis. Seven patients were excluded from combined operation 
because of either early brain relapse after craniotomy or single brain 
metastasis localization in deep brain structures. Forty-one of the 45 
patients who underwent combined operation had complete remission of 
neurologie symptoms. Actuarial 5-year survival from the second surgical 
intervention was 16% (median 19 months, range 1 to 104 months). NO 
status and lobectomy were the only variables associated with longer 
survival. Actuarial 5-year survivals in patients with synchronous and 
metachronous presentation were6.6% and 19%, respectively. In patients 
with metaehronous presentation the length of survival was significantly 
associated with NO status, lobectomy, and interval between lung and brain 
operation equal to or longer than 14.5 months. The subset of patients with 
NO status and interval between operations longer than 14.5 months had a 
61% 5-year survival. None of the patients with N1-2 disease and shorter 
interval between operations was alive at 20 months. These data indicate 
that prognostic factors may help to identify subsets of patients with 
markedly different outcomes after combined lung and brain operation. 
(J Thorac Cardiovasc Surg 1996;112:146-53) 
y he brain is a common site of non-small-cell lung 
cancer (NSCLC) relapse. 1 It has been estimated 
that in the United States about 40 thousand patients 
each year will have brain metastasis from NSCLC. 2 
Pathologic studies have shown that single brain 
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metastasization occurs in one third of the whole 
population of patients with brain metastasis from 
NSCLC. 3-7 It is evident, therefore, that a consider- 
able number of patients with NSCLC undergo eval- 
uation for removal of single brain metastasis (SBM). 
It has been repeatedly demonstrated that combined 
operation of primary NSCLC and SBM is superior 
to other treatments in prolonging survival and dis- 
ease-free interval, z' 8-29 The aim of this paper was to 
ascertain whether survival could be affected by 
prognostic variables of both NSCLC and SBM and 
the time interval between the two surgical proce- 
dures. 
Patients and methods 
We reviewed the clinical records and follow-up data of 
52 patients with NSCLC and SBM who, between January 
1975 and June 1992, were evaluated for radical combined 
lung and brain operation. 
In 19 patients the pulmonary and brain lesions were 
synchronous with neurologic symptoms as first clinical 
The Journal of Thoracic and 
Cardiovascular Surgery 
Volume 112, Number 1 
Mussi et aL 147 
Table I. Clinical characteristics of 15 patients with 
synchronous presentation of lung cancer and SBM 
treated by combined operation 
Male/female 15/0 
Median age (yr) 56.3 
Range (yr) 41-68 
Lung cancer 
Lobectomy/pneumonectomy 13/2 
Right/left site 7/8 
Upper/lower location 12/3 
Median size (cm) 4 
Range (cm) 2-9 
Histologic type 
Squamous 6 
Adenocarcinoma 7 
Undifferentiated 2 
T1-2/T3 status 13/2 
N0/N1-2 status 8/7 
Brain metastasis 
Right/left site 10/5 
Supratent orial/infratentorial location 12/3 
SBM,, Single brain metastasis. 
presentation. Fifteen of these patients underwent com- 
bined brain and lung resections. Brain operation preceded 
lung resection in all cases (median interval 1 month) to 
control neurologic symptoms and to avoid central nervous 
system complications after pulmonary resection. The clin- 
ical characteristics of these patients are reported in Table 
I. Lung resection was not done in four patients because of 
early brain relapse after craniotomy. 
In 33 patients SBM was diagnosed in a time interval 
equal to or longer than 2 months after NSCLC resection 
(metachronous presentation). Thirty of these patients 
underwent combined lung and brain resection with a 
median interval of 14.5 months (range 2 to 45 months). 
The clinical characteristics of these patients are reported 
in Table II. Brain resection was not done in three patients 
because of localization of the metastases in deep brain 
structures (medulla oblongata or basal ganglia). 
The lung and brain resection was defined as complete 
according to standard rules. Margins of brain and lung 
resections were negative for neoplastic infiltration at 
microscopic examination. All the resected lung specimens 
were examined pathologically according to the TNM 
system. 3° Differences between lung and brain histologic 
types were excluded by careful pathologic review of lung 
and brain neoplastic tissue of each patient. 
Six of seven patients with synchronous presentation a d 
N1-2 status and 5 of 11 patients with metachronous 
presentation a d N1-2 status received various regimens of 
adjuvant chemotherapy after lung operation. Eight pa- 
tients, two with synchronous and six with metachronous 
presentation, underwent whole brain irradiation with 30 
Gy in 15 fractions over 4 weeks. Three patients with T3 
tumors and metachronous presentation of SBM under- 
went chest wall radiotherapy after en bloc resection. 
Table II. Clinical characteristics of 30 patients with 
metachronous presentation of lung cancer and SBM 
treated by lung and subsequent brain operation 
Male/female 26/4 
Median age (yr) 57.5 
Range (yr) 33-72 
Lung cancer 
Lobectomy/pneumonectomy 22/8 
Right/left site 12/18 
Upper/lower location 26/4 
Median size (cm) 4 
Range (cm) 2-10 
Histologic type 
Squamous 9 
Adenocarcinoma 12 
Undifferentiated 9 
T1-2/T3 status 22/8 
N0/N1-2 status 19/11 
Brain metastasis 
Median interval (mo) 14.5 
Range (mo) 2-45 
Right/left site 16/14 
Supratentorial/infratentorial l cation 24/6 
SBM, Single brain metastasis. 
Survival time was measured from the date of the second 
surgical procedure (lung for patients with synchronous 
presentation and brain for patients with metachronous 
presentation) until death or the most-recent date of 
follow-up (December 1993) for those surviving. Survival 
was estimated by the Kaplan-Meier method 31 and com- 
parisons of survival for univariate analysis were estimated 
by Mantel-Cox and Breslow tests. 32' 33 Frequency data 
analysis was estimated by Fisher's exact test. The results 
were considered significant at the 0.05 level Co < 0.05). 
Results 
There were no operative deaths. Complete remis- 
sion of the neurologic symptoms was obtained in 41 
of the 45 patients who underwent combined opera- 
tion. The actuarial overall 5-year survival was 16% 
with a median survival of 19 months (range 1 to 104 
months) (Fig. 1). Thirty-six patients had relapse and 
died of the tumor. Table I I I  reports sites of relapse 
and disease-free interval from the second surgical 
intervention. A 77-year-old patient with a 47-month 
disease-free interval from time of brain operation 
died of cerebral ictus. By the univariate model 
(Table IV)~ the following did not affect survival: sex; 
age; site, size, location, histologic type, and T status 
of lung cancer; site and location of SBM; synchro- 
nous or metachronous presentation; and adjuvant 
therapy. By contrast, survival was significantly af- 
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Fig. 1. Actuarial 5-year survival of all patients treated by combined lung and brain operation. Median 
survival was 19 months for all patients. Patients with synchronous and metachronous presentations had 
median survivals of 18 and 19 months, respectively. 
Table III. Site of relapse and disease-free interval of 
36 patients treated by combined lung and brain 
operation who had relapse 
Median 
Site of disease-free interval 
relapse n (%) in months (range) 
Local 
Thorax 14 (39) 13.5 (2-95) 
Brain 8 (22) 14.5 (2-23) 
Systemic 14 (39) 2 (1-54) 
fected by type of lung resection (lobectomy versus 
pneumonectomy) (Fig. 2) and N status (NO versus 
N1-2) (Fig. 3). 
The 5-year survival rate of the 15 patients with 
synchronous presentation was 6.6% with a median 
survival of 18 months (Fig. 1). Fourteen of the 15 
patients died within 30 months. Only one patient 
survived more than 5 years (63 months). The only 
variable that was significantly associated with a 
longer survival was the presence of squamous lung 
cancer (p = 0.02). 
The 5-year actuarial survival of the 30 patients 
with metachronous presentation was 19% with a 
median survival of 19 months (Fig. 1). The variables 
Table IV. Univariate analysis of 45 patients with 
lung cancer and SBM (synchronous and 
metachronous) treated by combined operation 
Variables p Value 
Male vs female NS 
Age <57 vs >-57 yr NS 
Lung cancer 
Lobectomy vs pneumonectomy 0.040 
Right vs left site NS 
Size <4 vs ->4 cm NS 
Upper vs lower location NS 
Squamous vs nonsquamous histologic type NS 
T1-2 vs T3 status NS 
NO vs N1-2 status 0.009 
Brain metastatis 
Synchronous vs metachronous presentation NS 
Right vs left site NS 
Supratentorial vs infratentorial location NS 
Adjuvant therapy NS 
NS, Not significant; SBM, single brain metastasis. 
associated with a longer survival (Table V) were the 
type of lung resection (median survival of patients 
who underwent lobectomy and pneumonectomy was 
27 and 4 months, respectively), the N status (median 
survival of patients with NO and N1-2 tumors was 37 
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Fig. 2. Actuarial 5-year survival according to type of lung operation in 45 patients who underwent 
combined lung and brain operation. Median survival of patients who underwent lobectomy and 
pneumonectomy was 20 and 5 months, respectively. 
and 4 months, respectively), and the median interval 
between lung and brain operation (->14.5 months 
versus <14.5 months) (Fig. 4). 
With grouping of the 30 patients with metachro- 
nous presentation according to N status and interval 
between the two surgical procedures, the longest 
5-year survival (61%) was obtained in patients with 
NO status and interval between lung and brain 
operation equal to or longer than 14.5 months (p = 
0.004) (Fig. 5). All patients with N1-2 status and 
interval between surgical procedures horter than 
14.5 months died within 20 months. Combining N 
status with type of lung operation, there was 29% 
5-year survival in the 14 patients with NO status and 
lobectomy. Only one of the other 16 patients was 
alive at 5 years. Although statistical significance in 
survival was not reached among the small subgroups 
of patients combined according to type of lung 
intervention and interval between surgical proce- 
dures, the 12 patients who underwent SBM removal 
after a period equal to or longer than 14.5 months 
after a lobectomy had an actuarial 5-year survival of 
58%. On the contrary, none of the remaining 18 
patients was alive after 4 years. 
Discuss ion  
The results of this paper confirm previous data of 
the literature that show that combined lung and 
brain operation is an effective treatment to control 
symptoms and to prolong survival in patients with 
NSCLC and SBM. a' 8-29 Indeed, in the present series 
of patients the median survival was 19 months, 
whereas the r ported median survival in untreated 
patients or in those treated with other therapeutic 
modalities does not exceed 6 months. 2 
Furthermore, the present data indicate that sur- 
vival is greatly affected by the locoregional extension 
of the lung tumor. In fact, considering the whole 
population of patients, type of lung resection and N 
status were associated with significantly different 
survival probabilities. Survival was higher in patients 
who underwent lobectomy andin those who had NO 
status with respect o survival in patients who un- 
derwent pneumonectomy and those with N1-2 sta- 
tus. 
The other variables considered, including syn- 
chronous or metachronous presentation, did not 
attain significant differences as far as survival prob- 
ability was concerned. However, the survival at 5 
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Fig. 3. Actuarial 5-year survival according to N stage considering 45 patients who underwent combined 
lung and brain operation. Median survival for NO and N1-2 tumors was 28 and 12 months, respectively. 
Table V. Univariate analysis of 30 patients with 
metachronous presentation of lung cancer and SBM 
treated by combined operation 
Variables p Value 
Male vs female NS 
Age <57 vs ->57 yr NS 
Lung cancer 
Lobectomy vs pneumonectomy 0.024 
Right vs left site NS 
Size <4 vs ->4 cm NS 
Upper vs lower location NS 
Squamous vs nonsquamous histologic type NS 
T1-2 vs T3 status NS 
NO vs N1-2 status 0.026 
Brain metastatis 
Right vs left site NS 
Supratentorial vs infratentorial location NS 
Interval between treatments less than median 0.045 
or greater than or equal to median 
(14.5 mo) 
NS, Not significant; SBM, single brain metastasis. 
years was significantly higher (p = 0.007) in patients 
with metachronous presentation (31%, median 35 
months) with respect o survival in patients with 
synchronous presentation (6.6%, median 18 
months) when the time lapse from diagnosis of 
NSCLC to death or the date of the most-recent 
follow-up was considered for the computation, in- 
stead of the time from the second surgical interven- 
tion. The observation that a metachronous presen- 
tation could represent a favorable indication for 
prognosis was further suggested by the results ob- 
tained in the analysis of the prognostic factors in the 
30 patients with metachronous presentation. In- 
deed, a significant increase in survival probability 
was associated not only with a limited extension of 
NSCLC (lobectomy versus pneumonectomy and NO 
versus N1-2), but also with the length of the median 
interval between the two surgical procedures (-> 14.5 
months). 
Furthermore, the presence of more than one 
favorable prognostic factor in patients with meta- 
chronous presentation was associated with an even 
longer survival. As an example, patients with NO 
status and an interval between interventions equal 
to or longer than 14.5 months had  markedly 
different prognosis (median 34 months) with respect 
to the prognosis in patients with N1-2 status and a 
shorter interval (median 4 months). Although 
based on small subsets of patients, this observa- 
tion points to the relevance of the previously 
mentioned prognostic indicators to the therapeu- 
tic decision. Indeed, patients with poor prognostic 
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Fig. 4. Actuarial 5-year survival according to interval between lung and brain operation in 30 patients with 
metachronous presentation. Median surv val of patients with interval between treatments 14.5 months or 
longer was 34 months compared with 12 months for patients with interval less than 14.5 mo ths. 
factors will probably not receive great benefit 
from the removal of SBM. 
In the patients with synchronous presentation no 
definite prognostic factors were identified with the 
exception of a trend to a longer survival in patients 
with squamous cell carcinoma. 
As concerns adjuvant whole brain irradiation, 
Magilligan, iv Catinella, 26 and Hankins 34 and their 
associates showed a beneficial effect, whereas Burt 
and associates 2 did not find any significant increase 
in survival after postoperative brain irradiation. In a 
randomized study Patchell and colleagues 35demon- 
strated that patients who underwent operation plus 
whole brain irradiation had significantly onger sur- 
vival in comparison with patients treated only with 
whole brain irradiation. Our results based on a small 
number of patients who received adjuvant whole 
brain irradiation do not permit us to derive firm 
conclusions about the usefulness of this therapeutic 
modality. However, in the present study, the great 
majority of patients died as a consequence of ex- 
tracranial relapse of the tumor. This points to the 
superior elevance of the lung tumor local stage, as 
compared with that of the SBM, in determining the 
prognosis of these patients. This is further evi- 
denced in patients with metachronous presentation 
who at the time of the most-recent follow-up 
showed only a 13% rate of brain relapse. Given the 
high morbidity and the undesirable ffects con- 
nected with whole brain irradiation, it may be 
advisable to limit this treatment to selected cases. 
The small percentage ofcases in which the patient 
underwent adjuvant chemotherapy and the different 
therapeutic regimens adopted at different times 
during the course of the study do not permit us to 
derive general conclusions on this subject. 
The observation ofan association of the length of 
survival with the local stage of the lung tumor in the 
whole population of patients, as well as with the 
length of the interval from lung operation to brain 
relapse in patients with metachronous presentation, 
permits us to draw some considerations on the 
therapeutic approach to these patients with dismal 
prognoses. Although based on a small number of 
subjects, the results obtained in this study clearly 
indicate that the removal of SBM in patients with 
NSCLC has to be considered after accurate valua- 
tion of the prognostic factors involved. With an 
accuracy reasonably acceptable from the clinical 
point of view, great differences in the outcome can 
be anticipated in each patient. In general, it can be 
said that there are patients in whom removal of 
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Fig. 5. Actuarial 5-year survival ofpatients with metachronous presentation of SBM stratified according 
to N stage and interval between lung and brain operation. Median survival was 34 months for NO, 14.5 
months or longer; 4 months for N1-2, 14.5 months or longer; 24 months for NO, less than 14.5 months; and 
4 months for N1-2, less than 14.5 months. 
SBM could be viewed only as an effective means for 
symptomatic relief. This is particularly true for 
patients with locally advanced lung tumors, patients 
with synchronous presentation, and patients with a 
short interval between lung operation and brain 
relapse. In the latter group the observed short-term 
survival after brain operation is not significantly 
different from that obtainable with alternative ther- 
apies. For this reason, removal of SBM in this 
subgroup of patients is warranted only in accurately 
selected cases. By contrast, the excellent results 
obtained in patients with limited locoregional NSCLC 
involvement and a long interval between lung opera- 
tion and brain relapse point to a potential curative 
effect of SBM removal. This subgroup of patients 
demonstrates long-term survival by brain operation, a
result that cannot be achieved by other treatments. 
That a limited locoregional stage of the lung 
tumor had a favorable bearing on the outcome has 
been already observed by others. 17' 21, 24, 25 In agree- 
ment with this, Butt and associates 2 found that 
patients with complete resection of NSCLC survived 
significantly longer than those with residual ocore- 
gional disease. However, comparison of our data 
with those of Burt and associates z is not possible 
because those authors did not report an analysis of 
the prognostic factors in the subgroup of patients 
who had completely resectable locoregional disease. 
In conclusion, the data obtained provide further 
support to the therapeutic approach of combined 
brain and lung operation in patients with NSCLC 
and SBM and, furthermore, indicate that accurate 
disease staging and selection of patients may help 
identify subsets of patients who will obtain the 
greater benefit from this procedure in terms of 
length of survival. Confirmation of these results in a 
greater study population made of larger subsets of 
patients with different prognostic haracteristics is 
warranted to better define advantages and limits of 
this therapeutic procedure. 
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